Trial Profile
A Phase 1, Open-label, Non-randomized, Parallel Group, Single-dose Adaptive Study in Adults With Hepatic Impairment and Matched, Healthy Control Participants With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 Results evaluating the role of hepatic impairment on daprodustat pharmacokinetics, pharmacodynamics, and tolerability, published in the Clinical Pharmacology in Drug Development
- 21 Mar 2020 Results assessing the effect of mild and moderate hepatic impairment (HI) on daprodustat pharmaco-kinetics (PK) and pharmacodynamics (PD) presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 13 Sep 2018 Status changed from recruiting to completed.